Title Credit Type Event date Cost
Exploring Novel Strategies for LDL-C Combination Therapy to Decrease ASCVD Risk: A Paradigm Shift
    • 1.50 CDE
    • 1.50 ACPE Pharmacy
    • 1.50 AMA PRA Category 1 Credit™
    • 1.50 ANCC
    • 1.50 Participation
 Enduring $0.00
Ace the Case Challenge Series: Exploring Novel Strategies for LDL-C Combination Therapy to Decrease ASCVD Risk
    • 0.75 ACPE Pharmacy
    • 0.75 AMA PRA Category 1 Credit™
    • 0.75 ANCC
    • 0.75 Participation
 Enduring $0.00
Understanding the Role of Lp(a) as a CV Risk Marker to Therapeutic Target in the Prevention of ASCVD
    • 1.50 CDE
    • 1.50 ACPE Pharmacy
    • 1.50 AMA PRA Category 1 Credit™
    • 1.50 ANCC
    • 1.50 Participation
 Enduring $0.00
Ace the Case Challenge Series: The Intersection of MASH and Cardiometabolic Risk
    • 0.50 CDE
    • 0.50 ACPE Pharmacy
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 ANCC
    • 0.50 Participation
 Enduring $0.00
The Burden of Resistant Hypertension in Women: Novel and Emerging Approaches to Improve Outcomes
    • 0.50 ACPE Pharmacy
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 ANCC
    • 0.50 Participation
 Enduring $0.00
The Risk Stratification and Treatment of Chronic Kidney Disease in Women: Uncovering and Addressing Disparities to Improve Outcomes
    • 1.00 ACPE Pharmacy
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 ANCC
    • 1.00 Participation
 Enduring $0.00
Podcast - Ironing Out the Data: Iron Deficiency in Heart Failure
    • 0.50 ACPE Pharmacy
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 ANCC
    • 0.50 Participation
 Enduring $0.00
Optimizing the Recognition and Treatment of Chronic Kidney Disease in Patients with Type 2 Diabetes: What Primary Care Clinicians Need to Know
    • 1.25 ACPE Pharmacy
    • 1.25 AMA PRA Category 1 Credit™
    • 1.25 ANCC
    • 1.25 Participation
 Enduring $0.00
Dietary Strategies for Reversing Type 2 Diabetes: Advances, Perspectives, and Expert Discussions
    • 4.00 Participation
 Enduring $0.00
At the Forefront of Care for Patients with Worsening Heart Failure: New and Emerging Treatment Options
    • 1.25 ACPE Pharmacy
    • 1.25 AMA PRA Category 1 Credit™
    • 1.25 ANCC
    • 1.25 Participation
 Enduring $0.00
Addressing the Cardiometabolic Risk Continuum in MASH: What Clinicians Need to Know
    • 1.00 CDE
    • 1.00 ACPE Pharmacy
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 ANCC
    • 1.00 Participation
 Enduring $0.00
Clinical Brief: Advancements in Dyslipidemia Treatments and ASCVD Risk Reduction for High-Risk Individuals
    • 0.50 CDE
    • 0.50 ACPE Pharmacy
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 ANCC
    • 0.50 Participation
 Enduring $0.00